drugset / Trial / NCT00947895

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

NCT00947895

Phase 2/3 Terminated 30 enrolled Neurologique Foundation, Inc. Mallinckrodt · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare intramuscular (IM) ACTH (adrenocorticotropin hormone) and intravenous (IV) methylprednisolone (Solumedrol) for the treatment of an MS (Multiple Sclerosis) relapse (exacerbation) after sub-response to an initial 3 day course of IV methylprednisolone.

Timeline

Start
2009-10
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator ACTH Unknown 80 mg Intramuscular
Comparator Methylprednisolone Other / unclassified 1000 mg Intravenous

Indications